Stabilized MHC I
AssigneeImusyn GmbH & Co. KG
InventorClemens Schneeweiss
Life of this patent
Estimating the term…
Abstract
Modified MHC I molecules that can be expressed in cell culture and can be more stable than natural MHC I molecules. An analytical process uses the modified MHC I molecules, e.g. for determination of antibodies in a serum sample directed against these MHC I molecules. MHC I is provided which has at least one covalent bond formed between a Cystein in the alpha chain and a Cystein in the β2-microglobulin.
Claims13
An MHC I molecule comprising an alpha chain and a β2-microglobulin being devoid of a covalently linked cognate antigenic peptide while comprising at least one covalent bond that is formed between Cysteine residues of the pairs of amino acid residues selected from
- Amino acid position
- Amino acid position
- Pair No.
- of alpha chain
- of β2-microglobulin
- 1
- No. 120
- No. 31,
- wherein the alpha chain has at least 90% sequence identity with amino acids No. 3 to 272 of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 9, and the β2-microglobulin has at least 90% sequence identity with SEQ ID NO:
- 4, wherein the numbering of amino acid positions in the alpha chain and in the β2-microglobulin refers to the alpha chain (SEQ ID NOS:
- 1-3 or SEQ ID NO:
- 9) and the β2-microglobulin (SEQ ID NO:
- 4) without an N-terminal signal peptide.
Dependencies are inferred from the claim text.